Maintenance versus no Maintenance BCG Immunotherapy of Superficial Bladder Cancer
Publication Information Expand/Collapse
PMid: PMID27986655 | PMC number: PMC5370550
PMid: PMID27376138 | PMC number: PMC4927845
Association between BMI at treatment initiation and cancer survival across multiple SWOG trials
Failure to achieve a complete response to induction BCG therapy is associated with increased risk of progression and death in patients with high risk non-muscle invasive bladder cancer [PMC2695968; PMID18367117]
The Southwest Oncology Group: progress in cancer research [PMID18929152]
Patterns of recurrence and outcomes following induction bacillus calmette-guerin for high risk Ta, T1 bladder cancer [PMID17437798]
Timing of recurrence and outcomes following induction BCG for high risk Ta, T1 bladder cancer - a Southwest Oncology Group Trial
Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study
Maintenance BCG immunotherapy: Evidence of additional protection against cancer. A Southwest Oncology Group study.
Significant long-term patient benefit with BCG maintenance therapy: A Southwest Oncology Group study.
Maintenance BCG immunotherapy of superficial bladder cancer: A randomized prospective Southwest Oncology Group study.